Japan’s Takeda eyed Genzyme; unlikely to bid – WSJ
* Genzyme the target of $18.5 bln bid from Sanofi-Aventis
Read more on Reuters via Yahoo! Singapore News
Orexigen soars on Takeda deal; drug indexes slip
BOSTON (MarketWatch) — Orexigen Therapeutics was in the spotlight early Thursday as shares of the biotech group soared on news that Japanese pharmaceutical giant Takeda Pharmaceutical Co. has agreed to commercialize Orexigen’s new diet drug Contrave in North America, if and when it receives regulatory approval. Orexigen expects to receive a decision from the U.S. Food and Drug Administration on …
Read more on Market Watch
Powered by Yahoo! Answers
